title: [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
abstract: We report a case of pleural effusion, pericardial thickening, and pulmonary involvement in a patient with dry cough, dyspnea, edema, and changes in the skin of the lower limbs. Treatment with cabergoline (Sogilen) had been started 4 months earlier. Pleural effusion, pericardial thickening, and impaired pulmonary function (airflow obstruction, increased airway resistance, and reduced carbon monoxide diffusing capacity) were observed. The Naranjo scale pointed to a probable relationship between cabergoline and these adverse effects. We report on outcome after 2 months of follow-up, during which time there was a slow and incomplete improvement in respiratory function. This is the first case in our practice setting of early pleuropulmonary toxicity associated with cabergoline.
authors.affiliation: Servicio de Geriatría. Hospital del Mar. Hospital de la Esperanza, Centro Fórum, Instituto de Atención Geriátrica y Sociosanitaria (IAGS) Barcelona. España.
authors.forename: Christian
authors.initials: C
authors.lastname: Villavicencio
authors.forename: Alba
authors.initials: A
authors.lastname: Ramírez-Sarmiento
authors.forename: Angel
authors.initials: A
authors.lastname: Gayete
authors.forename: Santiago
authors.initials: S
authors.lastname: Grau
authors.forename: Mauricio
authors.initials: M
authors.lastname: Orozco-Levi
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D010996:Pleural Effusion / Q000139:chemically induced*; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline